A Phase 2 interventional study of CIN-107 and Placebo in Uncontrolled Hypertension, sponsored by CinCor Pharma, Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by CinCor Pharma, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.
Among the 18 studies testing baxdrostat in Hypertension, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 2nd registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 249 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 197 across the 18 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
This study is registered under CinCor Pharma, Inc., one of the names counted as AstraZeneca. Under that name alone:
CinCor Pharma, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
71 studies in Hypertension by AstraZeneca: 4 open now, 6 under way, 3 of them phase 3. Of 65 finished, 15 (23%) have results posted.
Among the 71 studies in Hypertension by AstraZeneca, this one is the 16th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 in phase 2, and was the 53rd registered.
AstraZeneca’s Hypertension studies by the year they started, since 1998.
1 of the studies testing baxdrostat in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing baxdrostat in Hypertension, from their registry updates:
Among AstraZeneca’s 71 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of baxdrostat (also called CIN-107) in the treatment of patients with uncontrolled hypertension. The primary objective was to demonstrate that treatment with baxdrostat for 8 weeks would lower the systolic blood pressure (SBP) in patients who were hypertensive despite taking one or two anti-hypertensive medications.
Participants were assigned to take placebo or baxdrostat once per day for 8 weeks while they continued taking the regular anti-hypertensive medications. At the end of the 8-week period, qualified patients could participate in Part II of the study and receive 2 mg baxdrostat for 4 weeks while they discontinued taking the background anti-hypertensive medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Drug: CIN-107
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Drug: CIN-107
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control
Drug: CIN-107
Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks
Drug: Placebo
CIN-107 tablets by mouth once daily
Also known as: Baxdrostat
Placebo tablets by mouth once daily
Change From Baseline in Mean Seated Systolic BP (SBP)
The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1).
Time frame: 8 weeks
Change From Baseline in Mean Seated Diastolic BP (DBP)
The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Time frame: 8 weeks
Change From Baseline in 24-hour Urine Aldosterone
The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
Time frame: 8 weeks
Change From Baseline in 24-hour Serum Aldosterone
The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
Time frame: 8 weeks
Percentage of Patients Achieving a Mean Seated SBP <130 mmHg
The percentage of patients achieving a mean seated SBP \<130 mmHg ("responders") with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8)
Time frame: 8 weeks
Change From Baseline in 24-hour Urine Renin
The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Time frame: 8 weeks
Change From Baseline in 24-hour Serum Renin
The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
Time frame: 8 weeks
| Milestone | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Part II - CIN-107 2mg |
|---|---|---|---|---|---|
| Started | 64 | 63 | 62 | 60 | 0 |
| Completed | 60 | 55 | 58 | 54 | 0 |
| Not completed | 4 | 8 | 4 | 6 | 0 |
| Milestone | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Part II - CIN-107 2mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 213 |
| Completed | 0 | 0 | 0 | 0 | 201 |
| Not completed | 0 | 0 | 0 | 0 | 12 |
The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1).
| mmHg | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Seated Systolic BP (SBP) | -16.6 ± 1.58 | -17.0 ± 1.63 | -16.0 ± 1.62 | -19.8 ± 1.67 |
The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
| mmHg | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Seated Diastolic BP (DBP) | -5.9 ± 1.17 | -5.8 ± 1.20 | -5.0 ± 1.19 | -5.4 ± 1.23 |
The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
| ng/g | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Change From Baseline in 24-hour Urine Aldosterone | -19.90 ± 29.183 | -114.16 ± 31.305 | -140.45 ± 29.999 | -121.64 ± 30.760 |
The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)
| ng/dL | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Change From Baseline in 24-hour Serum Aldosterone | -0.70 ± 0.490 | -2.76 ± 0.493 | -2.95 ± 0.508 | -2.92 ± 0.515 |
The percentage of patients achieving a mean seated SBP \<130 mmHg ("responders") with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8)
| Participants | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Percentage of Patients Achieving a Mean Seated SBP <130 mmHg | 36 | 36 | 33 | 43 |
The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
| ng/day | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Change From Baseline in 24-hour Urine Renin | -20.08 ± 16.584 | -6.54 ± 15.739 | -5.74 ± 10.703 | 4.11 ± 17.930 |
The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)
| ng/L | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg |
|---|---|---|---|---|
| Change From Baseline in 24-hour Serum Renin | 92.902 ± 144.3969 | 63.565 ± 195.0495 | 88.041 ± 91.2996 | -140.961 ± 151.5431 |
Collected over Part I - AEs during the 8-week treatment period Part II - AEs during the following 4-week treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/64 (0%) | 0/64 (0%) | 5/64 (7.8%) |
| CIN-107 0.5 mg | 0/63 (0%) | 0/63 (0%) | 8/63 (12.7%) |
| CIN-107 1 mg | 0/62 (0%) | 1/62 (1.6%) | 6/62 (9.7%) |
| CIN-107 2 mg | 1/60 (1.7%) | 1/60 (1.7%) | 3/60 (5%) |
| Part II - CIN-107 2 mg | 0/213 (0%) | 3/213 (1.4%) | 6/213 (2.8%) |
| Event | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Part II - CIN-107 2 mg |
|---|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/64 | 0/63 | 0/62 | 1/60 | 0/213 |
| Acute myocardial infarctionCardiac disorders | 0/64 | 0/63 | 1/62 | 0/60 | 0/213 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/64 | 0/63 | 0/62 | 0/60 | 1/213 |
| DizzinessNervous system disorders | 0/64 | 0/63 | 0/62 | 0/60 | 1/213 |
| Hypertensive urgencyVascular disorders | 0/64 | 0/63 | 0/62 | 0/60 | 1/213 |
| BradycardiaCardiac disorders | 0/64 | 0/63 | 0/62 | 0/60 | 1/213 |
| Event | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Part II - CIN-107 2 mg |
|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 3/64 | 0/63 | 5/62 | 3/60 | 6/213 |
| SARS-CoV-2 test positiveInvestigations | 2/64 | 4/63 | 1/62 | 0/60 | 0/213 |
| DiarrhoeaGastrointestinal disorders | 1/64 | 4/63 | 0/62 | 0/60 | 0/213 |
| Age, Categorical(Participants) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 37 | 37 | 41 | 155 |
| >=65 years | 24 | 26 | 25 | 19 | 94 |
| Age, Continuous(years) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| Mean | 60.5 ± 10.61 | 59.9 ± 10.85 | 61.2 ± 10.69 | 59.2 ± 11.88 | 60.2 ± 10.96 |
| Sex: Female, Male(Participants) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| Female | 37 | 28 | 37 | 30 | 132 |
| Male | 27 | 35 | 25 | 30 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 31 | 39 | 28 | 35 | 133 |
| Not Hispanic or Latino | 33 | 24 | 34 | 25 | 116 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 17 | 14 | 15 | 14 | 60 |
| White | 46 | 48 | 43 | 44 | 181 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 2 |
| Region of Enrollment(participants) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| United States | 64 | 63 | 62 | 60 | 249 |
| Seated SBP(mmHg) | Placebo | CIN-107 0.5 mg | CIN-107 1 mg | CIN-107 2 mg | Total |
|---|---|---|---|---|---|
| Mean | 147.9 ± 9.33 | 146.3 ± 8.60 | 147.0 ± 9.07 | 146.3 ± 7.83 | 146.9 ± 8.71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Sep 2022, 9 months.
Results were first posted in Aug 2023, 10 months after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 9 months is below that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baxdrostat